» Articles » PMID: 35286302

Does Plasmid-based Beta-lactam Resistance Increase E. Coli Infections: Modelling Addition and Replacement Mechanisms

Overview
Specialty Biology
Date 2022 Mar 14
PMID 35286302
Authors
Affiliations
Soon will be listed here.
Abstract

Infections caused by antibiotic-resistant bacteria have become more prevalent during past decades. Yet, it is unknown whether such infections occur in addition to infections with antibiotic-susceptible bacteria, thereby increasing the incidence of infections, or whether they replace such infections, leaving the total incidence unaffected. Observational longitudinal studies cannot separate both mechanisms. Using plasmid-based beta-lactam resistant E. coli as example we applied mathematical modelling to investigate whether seven biological mechanisms would lead to replacement or addition of infections. We use a mathematical neutral null model of individuals colonized with susceptible and/or resistant E. coli, with two mechanisms implying a fitness cost, i.e., increased clearance and decreased growth of resistant strains, and five mechanisms benefitting resistance, i.e., 1) increased virulence, 2) increased transmission, 3) decreased clearance of resistant strains, 4) increased rate of horizontal plasmid transfer, and 5) increased clearance of susceptible E. coli due to antibiotics. Each mechanism is modelled separately to estimate addition to or replacement of antibiotic-susceptible infections. Fitness costs cause resistant strains to die out if other strain characteristics are maintained equal. Under the assumptions tested, increased virulence is the only mechanism that increases the total number of infections. Other benefits of resistance lead to replacement of susceptible infections without changing the total number of infections. As there is no biological evidence that plasmid-based beta-lactam resistance increases virulence, these findings suggest that the burden of disease is determined by attributable effects of resistance rather than by an increase in the number of infections.

Citing Articles

The contribution of community transmission to the burden of hospital-associated pathogens: A systematic scoping review of epidemiological models.

Lin G, Poleon S, Hamilton A, Salvekar N, Jara M, Haghpanah F One Health. 2025; 20():100951.

PMID: 39816238 PMC: 11733049. DOI: 10.1016/j.onehlt.2024.100951.


New methodology to assess the excess burden of antibiotic resistance using country-specific parameters: a case study regarding urinary tract infections.

Godijk N, McDonald S, Altorf-van der Kuil W, Schoffelen A, Franz E, Bootsma M BMJ Open. 2023; 13(12):e064335.

PMID: 38110375 DOI: 10.1136/bmjopen-2022-064335.

References
1.
Andersson D, Hughes D . Antibiotic resistance and its cost: is it possible to reverse resistance?. Nat Rev Microbiol. 2010; 8(4):260-71. DOI: 10.1038/nrmicro2319. View

2.
Nijssen S, Florijn A, Bonten M, Schmitz F, Verhoef J, Fluit A . Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates. Int J Antimicrob Agents. 2004; 24(6):585-91. DOI: 10.1016/j.ijantimicag.2004.08.008. View

3.
de Kraker M, Jarlier V, Monen J, Heuer O, van de Sande N, Grundmann H . The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System. Clin Microbiol Infect. 2012; 19(9):860-8. DOI: 10.1111/1469-0691.12028. View

4.
Cooper B, Medley G, Stone S, Kibbler C, Cookson B, Roberts J . Methicillin-resistant Staphylococcus aureus in hospitals and the community: stealth dynamics and control catastrophes. Proc Natl Acad Sci U S A. 2004; 101(27):10223-8. PMC: 454191. DOI: 10.1073/pnas.0401324101. View

5.
Facinelli B, Spinaci C, Magi G, Giovanetti E, Varaldo P . Association between erythromycin resistance and ability to enter human respiratory cells in group A streptococci. Lancet. 2001; 358(9275):30-3. DOI: 10.1016/s0140-6736(00)05253-3. View